Company intelligence / Profile preview

CAP 28

Boston, Massachusetts, United Statesfao.org ↗

Ownership: Private
Development stage: Other

Overview

28 Capital is a Boston-based life sciences venture capital firm focused on translating cutting-edge academic science into breakthrough therapies by forming and scaling new biotech startups. The team has a track record of building transformative biotech companies through hands-on company creation and strategic investment partnerships with leading scientists and institutions.

Therapeutic areas: Rare Diseases
Modalities: TherapeuticsDiagnosticsSynthetic biology
Industry: Investors

Partnerships

Academic foundersTop-tier research institutions

Beyond the preview

Go deeper on CAP 28.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAP 28.

Explore the full profile